Arbeitsplatz zur Bruttoerzeugung für Pathologie-Labor | MEISTER

Grundinformation

• Verfügbar ab:
• English
• Deutsche

Product Description:
The EarlyTect Colon Cancer Test is a highly reliable and approved screening tool for colorectal cancer. It has undergone thorough clinical trials at renowned medical centers including Yonsei Medical Center, Severance Hospital, and Severance Check-up Center, under the approval of the Korea Ministry of Food and Drug Safety. The test was conducted on 585 men and women, aged 30 to 80, who were eligible subjects for the study.

Based on the clinical trials carried out using fecal DNA samples, the EarlyTect Colon Cancer Test has demonstrated an impressive 90% sensitivity and specificity in diagnosing colorectal cancer. This qualitative real-time PCR test focuses on measuring methylated Syndecan-2, which is a biomarker strongly associated with precancerous lesions of colorectal cancer, in the stool DNA. It should be noted that this test is not intended for confirming the presence of colorectal cancer. If a subject receives a positive result, it indicates the potential existence of colorectal cancer or precancerous lesions.

Product Standard:
- Cancer Type: Colorectal Cancer
- Subject: Designed for asymptomatic individuals seeking colorectal cancer screening
- Biomarker: SDC2 methylation

The price and transaction conditions for the EarlyTect Colon Cancer Test are negotiable. To receive detailed information regarding pricing and initiate a transaction, please kindly Request a Quote.